{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=aspart-+Insulin", "query": { "intervention": "aspart- Insulin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 180, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=aspart-+Insulin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T05:39:12.873Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01526733", "title": "Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Sham Injection", "type": "DRUG" }, { "name": "Recombinant human hyaluronidase PH20", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" }, { "name": "Insulin lispro", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2011-12", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01526733" }, { "nct_id": "NCT02100475", "title": "A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/liraglutide", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2014-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 7, "location_summary": "Fresno, California • Fort Lauderdale, Florida • Gurnee, Illinois + 4 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Gurnee", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Slidell", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02100475" }, { "nct_id": "NCT07076199", "title": "A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Insulin icodec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 877, "start_date": "2025-08-11", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 103, "location_summary": "Cullman, Alabama • Concord, California • Escondido, California + 85 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07076199" }, { "nct_id": "NCT00598793", "title": "Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "biphasic insulin aspart", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" }, { "name": "pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 242, "start_date": "2002-11", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 27, "location_summary": "Concord, California • Los Angeles, California • Walnut Creek, California + 20 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Melbourne", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00598793" }, { "nct_id": "NCT03260868", "title": "Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine, 300 units per milliliter (U/mL)", "type": "DRUG" }, { "name": "Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-09-19", "completion_date": "2018-11-22", "has_results": true, "last_update_posted_date": "2022-04-07", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 3, "location_summary": "West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia", "locations": [ { "city": "West Des Moines", "state": "Iowa" }, { "city": "Houston", "state": "Texas" }, { "city": "Bridgeport", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03260868" }, { "nct_id": "NCT01513473", "title": "A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "insulin degludec", "type": "DRUG" }, { "name": "insulin detemir", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 350, "start_date": "2012-01-16", "completion_date": "2013-07-30", "has_results": true, "last_update_posted_date": "2019-06-13", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 28, "location_summary": "Little Rock, Arkansas • Orange, California • San Diego, California + 23 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01513473" }, { "nct_id": "NCT05013229", "title": "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "IcoSema", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 679, "start_date": "2021-11-30", "completion_date": "2023-11-14", "has_results": false, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 66, "location_summary": "Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more", "locations": [ { "city": "Guntersville", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013229" }, { "nct_id": "NCT00097877", "title": "Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "biphasic insulin aspart", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 293, "start_date": "2005-01", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Vestavia Hills", "state": "Alabama" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00097877" }, { "nct_id": "NCT05946785", "title": "Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Gestational Diabetes", "Vascular Endothelial Function" ], "interventions": [ { "name": "Acetylcholine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anna Stanhewicz, PhD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 28, "start_date": "2023-07-01", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05946785" }, { "nct_id": "NCT01684943", "title": "Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Multiplex pharmacokinetic profiling", "type": "OTHER" }, { "name": "Continuous insulin monitoring", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2010-07", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2019-12-12", "last_synced_at": "2026-09-10T05:39:12.873Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01684943" } ] }